The Development of a Novel Nanobody Therapeutic for SARS-CoV-2

Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a novel series of single-domain antibodies (i.e., nanobody), Nanosota-1, from a camelid nanobody phage display library. Structural data showed that Nanosota-1 bound to the oft-hidden receptor-binding domain (RBD...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:bioRxiv
Egile Nagusiak: Ye, Gang, Gallant, Joseph P., Massey, Christopher, Shi, Ke, Tai, Wanbo, Zheng, Jian, Odle, Abby E., Vickers, Molly A., Shang, Jian, Wan, Yushun, Drelich, Aleksandra, Kempaiah, Kempaiah R., Tat, Vivian, Perlman, Stanley, Du, Lanying, Tseng, Chien-Te, Aihara, Hideki, LeBeau, Aaron M., Li, Fang
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Cold Spring Harbor Laboratory 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7685322/
https://ncbi.nlm.nih.gov/pubmed/33236012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.11.17.386532
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak